NASDAQ$SRRK
Scholar Rock Holding Corporation · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Scholar Rock reported Q1 2026 as a clinical-stage biotech with operating losses and no commercial product revenue.
For the quarter ended March 31, 2026, Scholar Rock (SRRK) continued clinical development of its spinal muscular atrophy and other muscle-focused therapies. The 10-Q reflects research and development spending, collaboration accounting, and general and administrative costs typical of a pre-commercial biopharma company.
- Pre-commercial biotech; revenue primarily collaboration-based if reported.
- R&D spend drives operating loss.
- Pipeline milestones determine investment thesis.
- Cash and equivalents support runway discussed in MD&A.
Headline financials
Revenue & EPS history
Scholar Rock · Revenue · Quarterly
$0
Forward guidance
No commercial revenue guidance; clinical milestones discussed in MD&A.
Tailwinds
- Differentiated muscle biology platform.
- Potential partnership economics.
Headwinds
- Operating losses until approval and launch.
- Clinical and regulatory execution risk.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2026
+3.6%
Avg return
Earnings day
+3.0%
Avg return
5 days after
+3.5%
Avg return
30 days after
58%
18 / 31 earnings
Positive
+24.6%
Q4 2023
Best reaction
-7.6%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.4% | +4.4% | -6.1% | |
| Q4 2025 | +2.0% | +4.2% | +15.0% | |
| Q3 2025 | +24.1% | +32.0% | +55.9% | |
| Q2 2025 | -6.1% | -14.9% | -15.1% | |
| Q1 2025 | -2.6% | -3.9% | +3.3% | |
| Q4 2024 | -2.9% | +0.2% | -11.3% | |
| Q3 2024 | -2.7% | -5.9% | +48.0% | |
| Q1 2024 | -3.7% | -11.4% | -37.4% | |
| Q4 2023 | +24.6% | +24.2% | +5.7% | |
| Q3 2023 | -1.8% | -17.5% | +44.2% | |
| Q2 2023 | +6.3% | +11.6% | -3.6% | |
| Q1 2023 | +4.4% | -0.1% | -13.6% | |
| Q4 2022 | +7.2% | -1.9% | -15.7% | |
| Q3 2022 | +10.9% | +0.2% | +1.5% | |
| Q2 2022 | +6.9% | +32.9% | +5.2% | |
| Q1 2022 | +7.3% | -5.2% | -9.7% | |
| Q4 2021 | -5.1% | -9.5% | -8.6% | |
| Q3 2021 | +16.8% | +24.2% | -10.4% | |
| Q2 2021 | +4.8% | +7.5% | +4.6% | |
| Q1 2021 | -2.4% | +0.1% | +10.6% | |
| Q4 2020 | +16.8% | +21.4% | -40.2% | |
| Q3 2020 | -1.0% | +2.8% | +7.7% | |
| Q2 2020 | +3.9% | -4.1% | +5.0% | |
| Q1 2020 | -4.8% | +6.9% | +2.2% | |
| Q4 2019 | +4.3% | +9.4% | -1.1% | |
| Q3 2019 | -7.6% | -14.5% | +17.0% | |
| Q2 2019 | +0.8% | +11.9% | +19.4% | |
| Q1 2019 | +6.2% | +8.6% | -4.9% | |
| Q4 2018 | +9.8% | +2.3% | -7.4% | |
| Q3 2018 | +2.0% | -10.0% | -1.6% | |
| Q2 2018 | -6.7% | -11.9% | +51.0% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro